reports
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Add...
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic i...
Abivax Announces Pricing of $650M (€554M) Public Offering of American ...
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering ...
Abivax announces trading resumption of its ordinary shares on Euronext...
Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from ...
- Jeremy Garnier
Abivax announces temporary trading halt of its ordinary shares on Euro...
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Eu...
Abivax Announces Launch of Public Offering
Abivax Announces Launch of Public Offering Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its Amer...
- Emmanuel Matot
TEMN TEMENOS AG
DKSH DKSH HOLDING AG
SSAB A SSAB AB CLASS A
EXE EXEL INDUSTRIES SA
HCO HIGHCO SA
ABVX ABIVAX SA
SOI SOITEC SA
TIETO TIETOEVRY OYJ
ENC ENCE ENERGIA Y CELULOSA SA
LFDE LA FRANCAISE DE L'ENERGIE SA
BRD BRD-GROUPE SOCIETE GENERALE
TLV BANCA TRANSILVANIA S.A.
COPN COSMO PHARMACEUTICALS NV
FTG111 FLATEXDEGIRO AG
ALD ALD SA
MVC METROVACESA SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
DSC1 DUTCH STAR C SHAR
VUL VULCAN ENERGY RESOURCES
- Emmanuel Matot
TEMN TEMENOS AG
DKSH DKSH HOLDING AG
SSAB A SSAB AB CLASS A
EXE EXEL INDUSTRIES SA
HCO HIGHCO SA
ABVX ABIVAX SA
SOI SOITEC SA
TIETO TIETOEVRY OYJ
ENC ENCE ENERGIA Y CELULOSA SA
LFDE LA FRANCAISE DE L'ENERGIE SA
BRD BRD-GROUPE SOCIETE GENERALE
TLV BANCA TRANSILVANIA S.A.
COPN COSMO PHARMACEUTICALS NV
FTG111 FLATEXDEGIRO AG
ALD ALD SA
MVC METROVACESA SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
DSC1 DUTCH STAR C SHAR
VUL VULCAN ENERGY RESOURCES
- Martial Descoutures
- Martial Descoutures
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Indu...
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis 50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p
- Luis de Toledo Heras
ITP INTERPARFUMS
WHA WERELDHAVE N.V.
HOT HOCHTIEF AG
A1XA4J CARBIOS SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
UCG UNICREDIT S.P.A.
ENG ENAGAS SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
DGM DIAGNOSTIC MEDICAL SYSTEMS
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
M MED LIFE
SCHOTT PHARMA AG
AQ AQUILA PART PROD COM
- Luis de Toledo Heras
ITP INTERPARFUMS
WHA WERELDHAVE N.V.
HOT HOCHTIEF AG
A1XA4J CARBIOS SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
UCG UNICREDIT S.P.A.
ENG ENAGAS SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
DGM DIAGNOSTIC MEDICAL SYSTEMS
BOSN BOSSARD HOLDING AG
SFSN SFS GROUP AG
M MED LIFE
SCHOTT PHARMA AG
AQ AQUILA PART PROD COM
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
GTT: Monthly disclosure of the total number of voting rights and share...
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, July 7, 2025 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2June 30, 202537,117,77237,117,77237,064,515 Investor Relations Contact / 87 1 Calculated on th...
GTT : Information mensuelle relative au nombre total de droits de vote...
GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 7 juillet 2025 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets230 juin 202537 117 77237 117 77237 064 515 Contact Relations Investisseurs : / 87 ...
GTT: Half-year liquidity contract statement
GTT: Half-year liquidity contract statement GTT: Half-year liquidity contract statement Saint-Rémy-lès-Chevreuse, July 7, 2025 Under the liquidity contract signed between GTT and Rothschild Martin Maurel, the following assets were booked to the liquidity account at June 30, 2025: 0 share€ 2,804,507 - Number of executions on buy side on semester: 5,166- Number of executions on sell side on semester: 5,625- Traded volume on buy side on semester: 177,593 shares for € 26,689,970.89- Traded volume on sell side on semester: 177,643 shares for € 26,681,419.51 As a reminder, the following reso...
GTT : Bilan semestriel du contrat de liquidité
GTT : Bilan semestriel du contrat de liquidité GTT : Bilan semestriel du contrat de liquidité Saint-Rémy-lès-Chevreuse, le 7 juillet 2025 Au titre du contrat de liquidité confié par la société GTT à Rothschild Martin Maurel, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : 0 titre2 804 507 € - Nombre de transactions exécutées sur le semestre à l’achat : 5 166- Nombre de transactions exécutées sur le semestre à la vente : 5 625- Volume échangé sur le semestre à l’achat : 177 593 titres pour 26 689 970,89 €- Volume échangé sur le semestre à la vente : 17...
Interparfums: 1 director
A director at Interparfums sold 1,000 shares at 37.540EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.